Designed multiple ligands for cancer therapy

Current Medicinal Chemistry

Volumn 18, Issue 31, 2011, Pages 4722-4737

  O'Boyle, N M ^a   Meegan, M J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cancer; Chemotherapy; Combination therapy; Conjugate; Designed multiple ligand; Dual target; Enzyme inhibition; Multi target; Multikinase inhibitors; Network pharmacology; Polypharmacy; Selectivity

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 ANILINO 9 METHOXY 5,7 DIHYDRO 6H PYRIMIDO[5,4 D][1] BENZAZEPIN 6 ONE; 4 [N (4 BROMOBENZYL) N (1,2,4 TRIAZOL 4 YL)AMINO]BENZONITRILE; 5 [2 (1H IMIDAZOL 1 YL)ETHYL] 5,6,7,8 TETRAHYDROQUINOLINE; ANASTROZOLE; AROMATASE INHIBITOR; BENZOPHENAZINE; BIS(MORPHOLINO 1,3,5 TRIAZINE); BOSUTINIB; BRIVANIB; DIAMINOFURO[2,3 D]PYRIMIDINE; DNA TOPOISOMERASE INHIBITOR; ELLIPTICINE; ETOPOSIDE; FOLIC ACID ANTAGONIST; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INTOPLICINE; IROSUSTAT; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; ENZYME INHIBITION; FOLATE METABOLISM; GASTROINTESTINAL TUMOR; HUMAN; IC 50; LIVER CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BIOCHEMICAL PROCESSES; DRUG DESIGN; FOLIC ACID; HUMANS; LIGANDS; NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOPOISOMERASE INHIBITORS;

EID: 80054868596     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797535344     Document Type: Article

References (116)

1. Espinoza-Fonseca, L.M. The benefits of the multi-target approach in drug design and discovery. Bioorg. Med. Chem., 2006, 14(4) 896-897. (Pubitemid 43059780)
2. Hopkins, A.L.; Mason, J.S.; Overington, J.P. Can we rationally design promiscuous drugs? Current Opinion in Structural Biology, 2006, 16(1) 127-136. (Pubitemid 43221881)
3. Keith, C.T.; Borisy, A.A.; Stockwell, B.R. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov, 2005, 4(1) 71-78. (Pubitemid 40109591)
4. Roth, B.L.; Sheffler, D.J.; Kroeze, W.K. Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov, 2004, 3(4) 353-359. (Pubitemid 38499762)
5. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discovery Today, 2004, 9(15) 641-651. (Pubitemid 38981718)
6. Meunier, B. Hybrid Molecules with a Dual Mode of Action: Dream or Reality? Accounts of Chemical Research, 2007, 41(1) 69-77.
7. Anai, S.; Sakamoto, N.; Sakai, Y.; Tanaka, M.; Porvasnik, S.; Urbanek, C.; Cao, W.; Goodison, S.; Rosser, C.J. Dual targeting of Bcl-2 and VEGF: A potential strategy to improve therapy for prostate cancer. Urologic Oncology: Seminars and Original Investigations, In Press, Corrected Proof.
8. Powers, M.V.; Clarke, P.A.; Workman, P. Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis. Cancer cell, 2008, 14(3) 250-262.
9. Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-Directed Ligands To Combat Neurodegenerative Diseases. J. Med. Chem., 2008, 51(3) 347-372. (Pubitemid 351252260)
10. Morphy, R.; Rankovic, Z. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm. J. Med. Chem., 2005, 48(21) 6523-6543. (Pubitemid 41504710)
11. Wei, D.; Jiang, X.; Zhou, L.; Chen, J.; Chen, Z.; He, C.; Yang, K.; Liu, Y.; Pei, J.; Lai, L. Discovery of Multitarget Inhibitors by Combining Molecular Docking with Common Pharmacophore Matching. J. Med. Chem., 2008, 51(24) 7882-7888.
12. Gediya, L.K.; Njar, V.C.O. Promise and challenges in drug discovery and development of hybrid anticancer drugs. Expert Opinion on Drug Discovery, 2009, 4(11) 1099-1111.
13. Viegas-Junior, C.; Danuello, A.; da Silva Bolzani, V.; Barreiro, E.J.; Fraga, C.A.M. Molecular Hybridization: A Useful Tool in the Design of New Drug Prototypes. Current Medicinal Chemistry, 2007, 14(17) 1829-1852. (Pubitemid 47163402)
14. Keely, N.O.; Meegan, M.J. Targeting Tumors Using Estrogen Receptor Ligand Conjugates. Current Cancer Drug Targets, 2009, 9(3) 370-380.
15. Hughes, B. Antibody-drug conjugates for cancer: Poised to deliver? Nat Rev Drug Discov, 2010, 9(9) 665-667.
16. DeCarvalho, S.; Rand, H.J.; Lewis, A. Coupling of Cyclic Chemotherapeutic Compounds to Immune Gamma-Globulins. Nature, 1964, 202(4929) 255-258.
17. Hampton, T. "Promiscuous" Anticancer Drugs That Hit Multiple Targets May Thwart Resistance. JAMA, 2004, 292(4) 419-422.
18. Corson, T.W.; Aberle, N.; Crews, C.M. Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One. ACS Chemical Biology, 2008, 3(11) 677-692.
19. Morphy, R.; Rankovic, Z. The Physicochemical Challenges of Designing Multiple Ligands. J. Med. Chem., 2006, 49(16) 4961-4970. (Pubitemid 44201054)
20. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 1997, 23, 3-25. (Pubitemid 27046991)
21. Veber, D.F.; Johnson, S.R.; Cheng, H.-Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem., 2002, 45(12), 2615-2623. (Pubitemid 34595232)
22. Johnston, S.R.D.; Dowsett, M. Aromatase inhibitors for breast cancer: Lessons from the laboratory. Nat Rev Cancer, 2003, 3(11) 821-831. (Pubitemid 37376980)
23. Woo, L.W.L.; Bubert, C.; Sutcliffe, O.B.; Smith, A.; Chander, S.K.; Mahon, M.F.; Purohit, A.; Reed, M.J.; Potter, B.V.L. Dual Aromatase-Steroid Sulfatase Inhibitors. J. Med. Chem., 2007, 50(15) 3540-3560. (Pubitemid 47195462)
24. Woo, L.W.L.; Jackson, T.; Putey, A.; Cozier, G.; Leonard, P.; Acharya, K.R.; Chander, S.K.; Purohit, A.; Reed, M.J.; Potter, B.V.L. Highly Potent First Examples of Dual Aromatase-Steroid Sulfatase Inhibitors based on a Biphenyl Template. J. Med. Chem., 2010, 53(5) 2155-2170.
25. Woo, L.W.L.; Sutcliffe, O.B.; Bubert, C.; Grasso, A.; Chander, S.K.; Purohit, A.; Reed, M.J.; Potter, B.V.L. First Dual Aromatase-Steroid Sulfatase Inhibitors. J. Med. Chem., 2003, 46(15) 3193-3196. (Pubitemid 36842404)
26. Jackson, T.; Woo, L.W.L.; Trusselle, M.N.; Chander, S.K.; Purohit, A.; Reed, M.J.; Potter, B.V.L. Dual aromatase-sulfatase inhibitors based on the anastrozole template: Synthesis, in vitro SAR, molecular modelling and in vivo activity. Organic & Biomolecular Chemistry, 2007, 5(18) 2940-2952.
27. Wood, P.M.; Woo, L.W.L.; Labrosse, J.-R.; Trusselle, M.N.; Abbate, S.; Longhi, G.; Castiglioni, E.; Lebon, F.; Purohit, A.; Reed, M.J.; Potter, B.V.L. Chiral Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole Template: Synthesis, Absolute Configuration, and In vitro Activity. J. Med. Chem., 2008, 51(14) 4226-4238. (Pubitemid 352032447)
28. Wood, P.M.; Woo, L.W.L.; Humphreys, A.; Chander, S.K.; Purohit, A.; Reed, M.J.; Potter, B.V.L. A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. The Journal of Steroid Biochemistry and Molecular Biology, 2005, 94(1-3) 123-130. (Pubitemid 40614525)
29. Numazawa, M.; Tominaga, T.; Watari, Y.; Tada, Y. Inhibition of estrone sulfatase by aromatase inhibitor-based estrogen 3-sulfamates. Steroids, 2006, 71(5) 371-379.
30. Jacobs, C.; Frotscher, M.; Dannhardt, G.; Hartmann, R.W. 1- Imidazolyl(alkyl)-Substituted Di- and Tetrahydroquinolines and Analogues: Syntheses and Evaluation of Dual Inhibitors of Thromboxane A2 Synthase and Aromatase. J. Med. Chem., 2000, 43(9) 1841-1851. (Pubitemid 30305016)
31. Yokoyama, I.; Hayashi, S.; Kobayashi, T.; Negita, M.; Yasutomi, M.; Uchida, K.; Takagi, H. Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor. Res. Exp. Med., 1995, 195(4) 209-215.
32. Geller, J. Basis for hormonal management of advanced prostate cancer Cancer 1993, 71, 1039-1045. (Pubitemid 23049629)
33. Hu, Q.; Jagusch, C.; Hille, U.E.; Haupenthal, J.; Hartmann, R.W. Replacement of Imidazolyl by Pyridyl in Biphenylmethylenes Results in Selective CYP17 and Dual CYP17/CYP11B1 Inhibitors for the Treatment of Prostate Cancer. J. Med. Chem., 2010, 53(15) 5749-5758.
34. Zhao, X.-Y.; Malloy, P.J.; Krishnan, A.V.; Swami, S.; Navone, N.M.; Peehl, D.M.; Feldman, D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med., 2000, 6(6) 703-706. (Pubitemid 30398797)
35. Kisliuk, R.L. The Biochemistry of Folates., In Folate Anagonists as Therapeutic Agents, F.M. Sirotnak, et al. ed.; Academic Press: New York, 1984; pp. 1-68.
36. Gangjee, A.; Jain, H.D.; Phan, J.; Lin, X.; Song, X.; McGuire, J.J.; Kisliuk, R.L. Dual Inhibitors of Thymidylate Synthase and Dihydrofolate Reductase as Antitumor Agents: Design, Synthesis, and Biological Evaluation of Classical and Nonclassical Pyrrolo[2,3-d]pyrimidine Antifolates. J. Med. Chem., 2006, 49(3) 1055-1065. (Pubitemid 43221653)
37. Gangjee, A.; Lin, X.; Kisliuk, R.L.; McGuire, J.J. Synthesis of N-{4-[(2,4- Diamino-5-methyl-4,7-dihydro-3H- pyrrolo[2,3-d]pyrimidin-6- yl)thio]benzoyl}-l-glutamic Acid and N-{4-[(2-Amino-4-oxo-5-methyl-4,7- dihydro-3H-pyrrolo[2,3-d]pyrimidin- 6-yl)thio]benzoyl}-l-glutamic Acid as Dual Inhibitors of Dihydrofolate Reductase and Thymidylate Synthase and as Potential Antitumor Agents. J. Med. Chem., 2005, 48(23) 7215-7222. (Pubitemid 41743635)
38. Gangjee, A.; Li, W.; Kisliuk, R.L.; Cody, V.; Pace, J.; Piraino, J.; Makin, J. Design, Synthesis, and X-ray Crystal Structure of Classical and Nonclassical 2-Amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as Dual Thymidylate Synthase and Dihydrofolate Reductase Inhibitors and as Potential Antitumor Agents. J. Med. Chem., 2009, 52(15) 4892-4902.
39. Gangjee, A.; Qiu, Y.; Li, W.; Kisliuk, R.L. Potent Dual Thymidylate Synthase and Dihydrofolate Reductase Inhibitors: Classical and Nonclassical 2-Amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine Antifolates. J. Med. Chem., 2008, 51(18) 5789-5797.
40. Gangjee, A.; Jain, H.D.; Phan, J.; Guo, X.; Queener, S.F.; Kisliuk, R.L. 2,4- Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors. Bioorg. Med. Chem., 2010, 18(2) 953-961.
41. Gangjee, A.; Li, W.; Yang, J.; Kisliuk, R.L. Design, Synthesis, and Biological Evaluation of Classical and Nonclassical 2-Amino-4-oxo-5- substituted-6-methylpyrrolo[3,2-d]pyrimidines as Dual Thymidylate Synthase and Dihydrofolate Reductase Inhibitors. J. Med. Chem., 2008, 51(1) 68-76.
42. Cline, S.D.; Macdonald, T.L.; Osheroff, N. Azatoxin Is a Mechanistic Hybrid of the Topoisomerase II-Targeted Anticancer Drugs Etoposide and Ellipticine. Biochemistry, 1997, 36(42) 13095-13101. (Pubitemid 27465425)
43. Cragg, G.M.; Kingston, D.G.; Newman, D.J. Anticancer Agents from Natural Products: CRC press: Florida, 2005.
44. Solary, E.; Leteurtre, F.; Paull, K.D.; Scudiero, D.; Hamel, E.; Pommier, Y. Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochemical Pharmacology, 1993, 45(12) 2449-2456. (Pubitemid 23189538)
45. Sackett, D.L. Podophyllotoxin, steganacin and combretastatin: Natural products that bind at the colchicine site of tubulin. Pharmacology & Therapeutics, 1993, 59(2) 163-228. (Pubitemid 23327192)
46. O'Boyle, N.M.; Carr, M.; Greene, L.M.; Bergin, O.; Nathwani, S.M.; McCabe, T.; Lloyd, D.G.; Zisterer, D.M.; Meegan, M.J. Synthesis and Evaluation of Azetidinone Analogues of Combretastatin A-4 as Tubulin Targeting Agents. J. Med. Chem., 2010, 53(24) 8569-8584.
47. Lefevre, D.; Riou, J.F.; Ahomadegbe, J.C.; Zhou, D.Y.; Benard, J.; Riou, G. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase. Biochem Pharmacol., 1991, 41(12) 1967-1979.
48. Vicker, N.; Burgess, L.; Chuckowree, I.S.; Dodd, R.; Folkes, A.J.; Hardick, D.J.; Hancox, T.C.; Miller, W.; Milton, J.; Sohal, S.; Wang, S.; Wren, S.P.; Charlton, P.A.; Dangerfield, W.; Liddle, C.; Mistry, P.; Stewart, A.J.; Denny, W.A. Novel Angular Benzophenazines: Dual Topoisomerase I and Topoisomerase II Inhibitors as Potential Anticancer Agents. J. Med. Chem., 2002, 45(3) 721-739. (Pubitemid 34145719)
49. Riou, J.-F.; Fosse, P.; Nguyen, C.H.; Larsen, A.K.; Bissery, M.-C.; Grondard, L.; Saucier, J.-M.; Bisagni, E.; Lavelle, F. Intoplicine (RP 60475) and Its Derivatives, a New Class of Antitumor Agents Inhibiting Both Topoisomerase I and II Activities. Cancer Research, 1993, 53(24) 5987-5993. (Pubitemid 24006171)
50. Thapa, U.; Thapa, P.; Karki, R.; Yun, M.; Choi, J.H.; Jahng, Y.; Lee, E.; Jeon, K.-H.; Na, Y.; Ha, E.-M.; Cho, W.-J.; Kwon, Y.; Lee, E.-S. Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. European Journal of Medicinal Chemistry, 2011, 46(8) 3201-3209.
51. de Jonge, M.J.A.; Kaye, S.; Verweij, J.; Brock, C.; Reade, S.; Scurr, M.; van Doorn, L.; Verheij, C.; Loos, W.; Brindley, C.; Mistry, P.; Cooper, M.; Judson, I. Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours. British Journal of Cancer, 2004, 91(8) 1459-1465. (Pubitemid 39486348)
52. Chen, L.; Wilson, D.; Jayaram, H.N.; Pankiewicz, K.W. Dual Inhibitors of Inosine Monophosphate Dehydrogenase and Histone Deacetylases for Cancer Treatment. J. Med. Chem., 2007, 50(26) 6685-6691. (Pubitemid 350309105)
53. Vizirianakis, I.S.; Chatzopoulou, M.; Bonovolias, I.D.; Nicolaou, I.; Demopoulos, V.J.; Tsiftsoglou, A.S. Toward the Development of Innovative Bifunctional Agents To Induce Differentiation and To Promote Apoptosis in Leukemia: Clinical Candidates and Perspectives. J. Med. Chem., 2010, 53(19) 6779-6810.
54. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone Deacetylase Inhibitors: From Bench to Clinic. J. Med. Chem., 2008, 51(6) 1505-1529. (Pubitemid 351438836)
55. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov, 2006, 5(9) 769-784. (Pubitemid 44348499)
56. Cameron, E.E.; Bachman, K.E.; Myohanen, S.; Herman, J.G.; Baylin, S.B. Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat Genet, 1999, 21(1) 103-107. (Pubitemid 29036293)
57. Yamamoto, M.; Ikeda, S.; Kondo, H.; Inoue, S. Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin. Bioorganic & Medicinal Chemistry Letters, 2002, 12(3) 375-378. (Pubitemid 34113906)
58. Marques, S.M.; Nuti, E.; Rossello, A.; Supuran, C.T.; Tuccinardi, T.; Martinelli, A.; Santos, M.A. Dual Inhibitors of Matrix Metalloproteinases and Carbonic Anhydrases: Iminodiacetyl-Based Hydroxamate- Benzenesulfonamide Conjugates. J. Med. Chem., 2008, 51(24) 7968-7979.
59. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002, 2(3) 161-174. (Pubitemid 37328786)
60. Overall, C.M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat. Rev. Cancer, 2002, 2(9) 657-672. (Pubitemid 37328917)
61. deSolms, S.J.; Ciccarone, T.M.; MacTough, S.C.; Shaw, A.W.; Buser, C.A.; Ellis-Hutchings, M.; Fernandes, C.; Hamilton, K.A.; Huber, H.E.; Kohl, N.E.; Lobell, R.B.; Robinson, R.G.; Tsou, N.N.; Walsh, E.S.; Graham, S.L.; Beese, L.S.; Taylor, J.S. Dual Protein Farnesyltransferase- Geranylgeranyltransferase-I Inhibitors as Potential Cancer Chemotherapeutic Agents. J. Med. Chem., 2003, 46(14) 2973-2984. (Pubitemid 36775921)
62. Sun, J.; Qian, Y.; Hamilton, A.D.; Sebti, S.M. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene, 1998, 16(11) 1467-1473. (Pubitemid 28151853)
63. MacTough, S.C.; deSolms, S.J.; Shaw, A.W.; Abrams, M.T.; Ciccarone, T.M.; Davide, J.P.; Hamilton, K.A.; Hutchinson, J.H.; Koblan, K.S.; Kohl, N.E.; Lobell, R.B.; Robinson, R.G.; Graham, S.L. Diaryl ether inhibitors of farnesyl-protein transferase. Bioorganic & Medicinal Chemistry Letters, 2001, 11(10) 1257-1260. (Pubitemid 32434346)
64. Cory, S.; Adams, J.M. The Bcl2 family: Regulators of the cellular life-ordeath switch. Nat. Rev. Cancer, 2002, 2(9) 647-656. (Pubitemid 37328916)
65. Bruncko, M.; Oost, T.K.; Belli, B.A.; Ding, H.; Joseph, M.K.; Kunzer, A.; Martineau, D.; McClellan, W.J.; Mitten, M.; Ng, S.-C.; Nimmer, P.M.; Oltersdorf, T.; Park, C.-M.; Petros, A.M.; Shoemaker, A.R.; Song, X.; Wang, X.; Wendt, M.D.; Zhang, H.; Fesik, S.W.; Rosenberg, S.H.; Elmore, S.W. Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem., 2007, 50(4) 641-662. (Pubitemid 46332978)
66. Park, C.-M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K.C.; Nimmer, P.; Shoemaker, A.R.; Song, X.; Tahir, S.K.; Tse, C.; Wang, X.; Wendt, M.D.; Yang, X.; Zhang, H.; Fesik, S.W.; Rosenberg, S.H.; Elmore, S.W. Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins. J. Med. Chem., 2008, 51(21) 6902-6915.
67. Tse, C.; Shoemaker, A.R.; Adickes, J.; Anderson, M.G.; Chen, J.; Jin, S.; Johnson, E.F.; Marsh, K.C.; Mitten, M.J.; Nimmer, P.; Roberts, L.; Tahir, S.K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S.H.; Elmore, S.W. ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. Cancer Research, 2008, 68(9) 3421-3428.
68. Knox, A.J.S.; Price, T.; Pawlak, M.; Golfis, G.; Flood, C.T.; Fayne, D.; Williams, D.C.; Meegan, M.J.; Lloyd, D.G. Integration of Ligand and Structure-Based Virtual Screening for the Identification of the First Dual Targeting Agent for Heat Shock Protein 90 (Hsp90) and Tubulin. J. Med. Chem., 2009, 52(8) 2177-2180.
69. Chiosis, G. Discovery and Development of Purine-Scaffold Hsp90 Inhibitors. Current Topics in Medicinal Chemistry, 2006, 6(11) 1183-1191. (Pubitemid 44110929)
70. Morphy, R. Selectively Nonselective Kinase Inhibition: Striking the Right Balance. J. Med. Chem., 2010, 53(4) 1413-1437.
71. Petrelli, A.; Giordano, S. From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage. Current Medicinal Chemistry, 2008, 15, 422-432. (Pubitemid 351472408)
72. Faivre, S.; Demetri, G.; Sargent, W.; Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov, 2007, 6(9) 734-745. (Pubitemid 47338181)
73. Buchdunger, E.; O'Reilley, T.; Wood, J. Pharmacology of imatinib (STI571). European Journal of Cancer, 2002, 38, S28-S36.
74. Harrison, C. Anticancer drugs: A double strike at kinases. Nat Rev Drug Discov, 2010, 9(4) 270-271.
75. Zhang, Y.-M.; Cockerill, S.; Guntrip, S.B.; Rusnak, D.; Smith, K.; Vanderwall, D.; Wood, E.; Lackey, K. Synthesis and SAR of potent EGFR/erbB2 dual inhibitors. Bioorganic & Medicinal Chemistry Letters, 2004, 14(1) 111-114. (Pubitemid 38010204)
76. Karaman, M.W.; Herrgard, S.; Treiber, D.K.; Gallant, P.; Atteridge, C.E.; Campbell, B.T.; Chan, K.W.; Ciceri, P.; Davis, M.I.; Edeen, P.T.; Faraoni, R.; Floyd, M.; Hunt, J.P.; Lockhart, D.J.; Milanov, Z.V.; Morrison, M.J.; Pallares, G.; Patel, H.K.; Pritchard, S.; Wodicka, L.M.; Zarrinkar, P.P. A quantitative analysis of kinase inhibitor selectivity. Nat Biotech, 2008, 26(1) 127-132.
77. Morphy, R. Selectively Nonselective Kinase Inhibition: Striking the Right Balance. J. Med. Chem., 2009, 53(4) 1413-1437.
78. Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov, 2009, 8(8) 627-644.
79. Garlich, J.R.; De, P.; Dey, N.; Su, J.D.; Peng, X.; Miller, A.; Murali, R.; Lu, Y.; Mills, G.B.; Kundra, V.; Shu, H.K.; Peng, Q.; Durden, D.L. A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity. Cancer Research, 2008, 68(1) 206-215. (Pubitemid 351380122)
80. Venkatesan, A.M.; Dehnhardt, C.M.; Delos Santos, E.; Chen, Z.; Dos Santos, O.; Ayral-Kaloustian, S.; Khafizova, G.; Brooijmans, N.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Gibbons, J.; Abraham, R.T.; Chaudhary, I.; Mansour, T.S. Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5'-Triphosphate Competitive Phosphatidylinositol-3- kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor. J. Med. Chem., 2010, 53(6) 2636-2645.
81. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S.-i.; Raynaud, F.I.; Workman, P.; Waterfield, M.D.; Parker, P. Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110[alpha] inhibitors. Bioorganic & Medicinal Chemistry Letters, 2007, 17(9) 2438-2442. (Pubitemid 46507793)
82. Apsel, B.; Blair, J.A.; Gonzalez, B.; Nazif, T.M.; Feldman, M.E.; Aizenstein, B.; Hoffman, R.; Williams, R.L.; Shokat, K.M.; Knight, Z.A. Targeted polypharmacology: D iscovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nature Chemical Biology, 2008, 4(11) 691-699.
83. Fan, Q.-W.; Knight, Z.A.; Goldenberg, D.D.; Yu, W.; Mostov, K.E.; Stokoe, D.; Shokat, K.M.; Weiss, W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 2006, 9(5) 341-349. (Pubitemid 43668732)
84. Knight, Z.A.; Gonzalez, B.; Feldman, M.E.; Zunder, E.R.; Goldenberg, D.D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W.A.; Williams, R.L.; Shokat, K.M. A Pharmacological Map of the PI3-K Family Defines a Role for p110alpha in Insulin Signaling. Cell, 2006, 125(4) 733-747.
85. Maira, S.-M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia- Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics, 2008, 7(7) 1851-1863.
86. Cited 16th December 2010; Available from: Www.clinicaltrials.gov
87. Dehnhardt, C.M.; Venkatesan, A.M.; Delos Santos, E.; Chen, Z.; Santos, O.; Ayral-Kaloustian, S.; Brooijmans, N.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Chaudhary, I.; Yu, K.; Gibbons, J.; Abraham, R.; Mansour, T.S. Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402. J. Med. Chem., 2009, 53(2) 798-810.
88. Sutherlin, D.P.; Sampath, D.; Berry, M.; Castanedo, G.; Chang, Z.; Chuckowree, I.; Dotson, J.; Folkes, A.; Friedman, L.; Goldsmith, R.; Heffron, T.; Lee, L.; Lesnick, J.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Olivero, A.; Pang, J.; Prior, W.W.; Salphati, L.; Sideris, S.; Tian, Q.; Tsui, V.; Wan, N.C.; Wang, S.; Wiesmann, C.; Wong, S.; Zhu, B.-Y. Discovery of (Thienopyrimidin-2- yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer. J. Med. Chem., 2010, 53(3) 1086-1097.
89. Ferrara, N.; Kerbel, R.S. Angiogenesis as a therapeutic target. Nature, 2005, 438(7070) 967-974. (Pubitemid 43093963)
90. Thompson, A.M.; Delaney, A.M.; Hamby, J.M.; Schroeder, M.C.; Spoon, T.A.; Crean, S.M.; Showalter, H.D.H.; Denny, W.A. Synthesis and Structure-Activity Relationships of Soluble 7-Substituted 3-(3,5- Dimethoxyphenyl)-1,6- naphthyridin-2-amines and Related Ureas as Dual Inhibitors of the Fibroblast Growth Factor Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinases. J. Med. Chem., 2005, 48(14) 4628-4653. (Pubitemid 40993423)
91. Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J.Y.; Chu, J.-Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T.C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)- ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2- Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase. J. Med. Chem., 2003, 46(7) 1116-1119. (Pubitemid 36428215)
92. Frey, R.R.; Curtin, M.L.; Albert, D.H.; Glaser, K.B.; Pease, L.J.; Soni, N.B.; Bouska, J.J.; Reuter, D.; Stewart, K.D.; Marcotte, P.; Bukofzer, G.; Li, J.; Davidsen, S.K.; Michaelides, M.R. 7-Aminopyrazolo[1,5-alpha]pyrimidines as Potent Multitargeted Receptor Tyrosine Kinase Inhibitors. J. Med. Chem., 2008, 51(13) 3777-3787. (Pubitemid 351956509)
93. Dinges, J.; Ashworth, K.L.; Akritopolou-Zanze, I.; Arnold, L.D.; Baumeister, S.A.; Bousquet, P.F.; Cunha, G.A.; Davidsen, S.K.; Djuric, S.W.; Gracias, V.J.; Michaelides, M.R.; Rafferty, P.; Sowin, T.J.; Stewart, K.D.; Xia, Z.; Zhang, H.Q. 1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters, 2006, 16(16) 4266-4271.
94. Hasegawa, M.; Nishigaki, N.; Washio, Y.; Kano, K.; Harris, P.A.; Sato, H.; Mori, I.; West, R.I.; Shibahara, M.; Toyoda, H.; Wang, L.; Nolte, R.T.; Veal, J.M.; Cheung, M. Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and VEGFR-2 Tyrosine Kinase Receptors. J. Med. Chem., 2007, 50(18) 4453-4470. (Pubitemid 47378842)
95. Wissner, A.; Fraser, H.L.; Ingalls, C.L.; Dushin, R.G.; Floyd, M.B.; Cheung, K.; Nittoli, T.; Ravi, M.R.; Tan, X.; Loganzo, F. Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Bioorg. Med. Chem., 2007, 15(11) 3635-3648. (Pubitemid 46635150)
96. Gangjee, A.; Namjoshi, O.A.; Yu, J.; Ihnat, M.A.; Thorpe, J.E.; Warnke, L.A. Design, synthesis and biological evaluation of substituted pyrrolo[2,3- d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents. Bioorg. Med. Chem., 2008, 16(10) 5514-5528. (Pubitemid 351694487)
97. Sun, L.; Tran, N.; Liang, C.; Hubbard, S.; Tang, F.; Lipson, K.; Schreck, R.; Zhou, Y.; McMahon, G.; Tang, C. Identification of Substituted 3-[(4,5,6,7- Tetrahydro-1H-indol-2-yl)methylene]- 1,3-dihydroindol-2-ones as Growth Factor Receptor Inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGFRbeta Tyrosine Kinases. J. Med. Chem., 2000, 43(14) 2655-2663. (Pubitemid 30463914)
98. Mahboobi, S.; Uecker, A.; Sellmer, A.; Cenac, C.; Hocher, H.; Pongratz, H.; Eichhorn, E.; Hufsky, H.; Trumpler, A.; Sicker, M.; Heidel, F.; Fischer, T.; Stocking, C.; Elz, S.; Bohmer, F.-D.; Dove, S. Novel Bis(1H-indol-2- yl)methanones as Potent Inhibitors of FLT3 and Platelet-Derived Growth Factor Receptor Tyrosine Kinase. J. Med. Chem., 2006, 49(11) 3101-3115. (Pubitemid 43830510)
99. Egert-Schmidt, A.-M.; Dreher, J.; Dunkel, U.; Kohfeld, S.; Preu, L.; Weber, H.; Ehlert, J.E.; Mutschler, B.; Totzke, F.; Schachtele, C.; Kubbutat, M.H.G.; Baumann, K.; Kunick, C. Identification of 2-Anilino-9-methoxy-5,7- dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as Dual PLK1/VEGF-R2 Kinase Inhibitor Chemotypes by Structure-Based Lead Generation. J. Med. Chem., 2010, 53(6) 2433-2442.
100. Thompson, A.M.; Connolly, C.J.C.; Hamby, J.M.; Boushelle, S.; Hartl, B.G.; Amar, A.M.; Kraker, A.J.; Driscoll, D.L.; Steinkampf, R.W.; Patmore, S.J.; Vincent, P.W.; Roberts, B.J.; Elliott, W.L.; Klohs, W.; Leopold, W.R.; Showalter, H.D.H.; Denny, W.A. 3-(3,5-Dimethoxyphenyl)-1,6- naphthyridine-2,7- diamines and Related 2-Urea Derivatives Are Potent and Selective Inhibitors of the FGF Receptor-1 Tyrosine Kinase. J. Med. Chem., 2000, 43(22) 4200-4211.
101. Borzilleri, R.M.; Zheng, X.; Qian, L.; Ellis, C.; Cai, Z.-w.; Wautlet, B.S.; Mortillo, S.; Jeyaseelan, R.; Kukral, D.W.; Fura, A.; Kamath, A.; Vyas, V.; Tokarski, J.S.; Barrish, J.C.; Hunt, J.T.; Lombardo, L.J.; Fargnoli, J.; Bhide, R.S. Design, Synthesis, and Evaluation of Orally Active 4-(2,4-Difluoro-5- (methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Inhibitors. J. Med. Chem., 2005, 48(12) 3991-4008. (Pubitemid 40800608)
102. Hunt, J.T.; Mitt, T.; Borzilleri, R.; Gullo-Brown, J.; Fargnoli, J.; Fink, B.; Han, W.-C.; Mortillo, S.; Vite, G.; Wautlet, B.; Wong, T.; Yu, C.; Zheng, X.; Bhide, R. Discovery of the Pyrrolo[2,1-f][1,2,4]triazine Nucleus as a New Kinase Inhibitor Template. J. Med. Chem., 2004, 47(16) 4054-4059. (Pubitemid 38970966)
103. Bhide, R.S.; Cai, Z.-W.; Zhang, Y.-Z.; Qian, L.; Wei, D.; Barbosa, S.; Lombardo, L.J.; Borzilleri, R.M.; Zheng, X.; Wu, L.I.; Barrish, J.C.; Kim, S.- H.; Leavitt, K.; Mathur, A.; Leith, L.; Chao, S.; Wautlet, B.; Mortillo, S.; Jeyaseelan, R.; Kukral, D.; Hunt, J.T.; Kamath, A.; Fura, A.; Vyas, V.; Marathe, P.; D'Arienzo, C.; Derbin, G.; Fargnoli, J. Discovery and Preclinical Studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-ol (BMS-540215), an In vivo Active Potent VEGFR-2 Inhibitor. J. Med. Chem., 2006, 49(7) 2143-2146.
104. Jain, R.K.; Duda, D.G.; Clark, J.W.; Loeffler, J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Prac Oncol, 2006, 3(1) 24-40. (Pubitemid 43108832)
105. Cai, Z.-w.; Zhang, Y.; Borzilleri, R.M.; Qian, L.; Barbosa, S.; Wei, D.; Zheng, X.; Wu, L.; Fan, J.; Shi, Z.; Wautlet, B.S.; Mortillo, S.; Jeyaseelan, R.; Kukral, D.W.; Kamath, A.; Marathe, P.; DeArienzo, C.; Derbin, G.; Barrish, J.C.; Robl, J.A.; Hunt, J.T.; Lombardo, L.J.; Fargnoli, J.; Bhide, R.S. Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1Hindol- 5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2- aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215). J. Med. Chem., 2008, 51(6) 1976-1980. (Pubitemid 351438880)
106. Huang, W.-S.; Zhu, X.; Wang, Y.; Azam, M.; Wen, D.; Sundaramoorthi, R.; Thomas, R.M.; Liu, S.; Banda, G.; Lentini, S.P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J.T.; Broudy, M.I.; Russian, K.; Daley, G.Q.; Iuliucci, J.; Dalgarno, D.C.; Clackson, T.; Sawyer, T.K.; Shakespeare, W.C. 9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation. J. Med. Chem., 2009, 52(15) 4743-4756.
107. Manetti, F.; Locatelli, G.A.; Maga, G.; Schenone, S.; Modugno, M.; Forli, S.; Corelli, F.; Botta, M. A Combination of Docking/Dynamics Simulations and Pharmacophoric Modeling To Discover New Dual c-Src/Abl Kinase Inhibitors. J. Med. Chem., 2006, 49(11) 3278-3286. (Pubitemid 43830525)
108. Golas, J.M.; Arndt, K.; Etienne, C.; Lucas, J.; Nardin, D.; Gibbons, J.; Frost, P.; Ye, F.; Boschelli, D.H.; Boschelli, F. SKI-606, a 4-Anilino-3- quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice. Cancer Research, 2003, 63(2) 375-381. (Pubitemid 36152495)
109. Boschelli, D.H.; Wang, Y.D.; Johnson, S.; Wu, B.; Ye, F.; Barrios Sosa, A.C.; Golas, J.M.; Boschelli, F. 7-Alkoxy-4-phenylamino-3- quinolinecarbonitriles as Dual Inhibitors of Src and Abl Kinases. J. Med. Chem., 2004, 47(7) 1599-1601. (Pubitemid 38380903)
110. Azam, M.; Nardi, V.; Shakespeare, W.C.; Metcalf, C.A.; Bohacek, R.S.; Wang, Y.; Sundaramoorthi, R.; Sliz, P.; Veach, D.R.; Bornmann, W.G.; Clarkson, B.; Dalgarno, D.C.; Sawyer, T.K.; Daley, G.Q. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proceedings of the National Academy of Sciences, 2006, 103(24) 9244-9249. (Pubitemid 43902563)
111. Hennequin, L.F.; Allen, J.; Breed, J.; Curwen, J.; Fennell, M.; Green, T.P.; Lambert-van der Brempt, C.; Morgentin, R.; Norman, R.A.; Olivier, A.; Otterbein, L.; Ple, P.A.; Warin, N.; Costello, G. N-(5-Chloro-1,3- benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2Hpyran- 4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor. J. Med. Chem., 2006, 49(22) 6465-6488. (Pubitemid 44657442)
112. Zhang, C.; Tan, C.; Zu, X.; Zhai, X.; Liu, F.; Chu, B.; Ma, X.; Chen, Y.; Gong, P.; Jiang, Y. Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors. European Journal of Medicinal Chemistry, 2011, 46(4) 1404-1414.
113. Lai, C.; Tao, X.; Liu, S.; Liu, Y.; Zhang, L.; Bao, R.; Cai, X.; Zhai, H.-X.; Qian, C. CU-0201, a potent, small molecule, multi-targeted inhibitor of HDAC, Abl and Src, effectively inhibits proliferation of both hematological and solid-tumor derived cancer cell lines. AACR Meeting Abstracts, 2008, 2008, 5717.
114. Gangjee, A.; Zeng, Y.; Ihnat, M.; Warnke, L.A.; Green, D.W.; Kisliuk, R.L.; Lin, F.-T. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Bioorg. Med. Chem., 2005, 13(18) 5475-5491. (Pubitemid 41132624)
115. Gangjee, A.; Li, W.; Lin, L.; Zeng, Y.; Ihnat, M.; Warnke, L.A.; Green, D.W.; Cody, V.; Pace, J.; Queener, S.F. Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors. Bioorg. Med. Chem., 2009, 17(20) 7324-7336.
116. Gangjee, A.; Zaware, N.; Raghavan, S.; Ihnat, M.; Shenoy, S.; Kisliuk, R.L. Single Agents with Designed Combination Chemotherapy Potential: Synthesis and Evaluation of Substituted Pyrimido[4,5-b]indoles as Receptor Tyrosine Kinase and Thymidylate Synthase Inhibitors and as Antitumor Agents. J. Med. Chem., 2010, 53(4) 1563-1578.